Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Evaluating the Anti-Osteoarthritis Potential of Standardized Boswellia serrata Gum Resin Extract in Alleviating Knee Joint Pathology and Inflammation in Osteoarthritis-Induced Models.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • الموضوع:
    • نبذة مختصرة :
      Osteoarthritis is a widespread chronic degenerative disease marked by the deterioration of articular cartilage, modifications in subchondral bone, and a spectrum of symptoms, including pain, stiffness, and disability. Ultimately, this condition impairs the patient's quality of life. This study aimed to evaluate the therapeutic efficacy of standardized Boswellia serrata gum resin extract (BSRE) in a rat model of monosodium iodoacetate (MIA)-induced osteoarthritis. A total of 60 rats were allocated into six groups: normal control group (NC), osteoarthritis control (injected with MIA, OC), O + B50 (injected with MIA and treated with 50 mg/kg body weight (BW) BSRE), O + B75 (injected with MIA and treated with 75 mg/kg BW BSRE), O + B100 (injected with MIA and treated with 100 mg/kg BW BSRE), and O + M (injected with MIA and treated with 150 mg/kg BW methyl sulfonyl methane). Several parameters, including knee joint swelling, histopathological changes, and the expression of collagen type II alpha 1 (COL2A1) and aggrecan, were comprehensively assessed. Concurrently, the serum levels and mRNA expression of inflammatory mediators, cytokines, and matrix metalloproteinases (MMPs) were analyzed in both the serum and knee joint synovium. The results demonstrated that BSRE significantly mitigated knee joint swelling, cartilage destruction, and tissue deformation. Notably, BSRE administration markedly upregulated the expression of COL2A1 and aggrecan while concurrently reducing levels of nitric oxide, prostaglandin E2, leukotriene B4, interleukin (IL)-6, and tumor necrosis factor (TNF)-α. Furthermore, a substantial decrease was observed in the mRNA expression of inducible nitric oxide synthase, cyclooxygenase-2, 5-lipoxygenase, IL-6, TNF-α and MMP-3 and -13, thereby indicating promising therapeutic implications for osteoarthritis. In conclusion, BSRE exhibited anti-inflammatory properties and inhibited cartilage matrix degradation in a rat model of MIA-induced osteoarthritis, with the O + B100 group showing significant reductions in swelling and notable improvements in joint cartilage damage. These findings illuminate the preventive and therapeutic potential of BSRE for osteoarthritis treatment, emphasizing the criticality of exhaustive evaluation of novel compounds.
    • References:
      Front Pharmacol. 2019 May 31;10:570. (PMID: 31214026)
      J Korean Acad Nurs. 2014 Feb;44(1):75-85. (PMID: 24637288)
      Clin Med Insights Arthritis Musculoskelet Disord. 2022 Mar 25;15:11795441211063365. (PMID: 35360183)
      Nat Prod Res. 2017 Jun;31(11):1309-1313. (PMID: 27737573)
      J Med Food. 2020 Aug;23(8):811-817. (PMID: 32614635)
      Rom J Morphol Embryol. 2010;51(2):215-28. (PMID: 20495735)
      Mediators Inflamm. 2014;2014:561459. (PMID: 24876674)
      Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S17-23. (PMID: 20864019)
      Clin Pharmacokinet. 2011 Jun;50(6):349-69. (PMID: 21553931)
      Front Pharmacol. 2021 May 04;12:680585. (PMID: 34017261)
      J Ethnopharmacol. 2013 Oct 7;149(3):816-24. (PMID: 23954277)
      Curr Issues Mol Biol. 2022 Aug 05;44(8):3481-3495. (PMID: 36005136)
      World J Clin Cases. 2015 Feb 16;3(2):89-101. (PMID: 25685755)
      Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589. (PMID: 31278997)
      Mol Med Rep. 2017 May;15(5):2853-2858. (PMID: 28447732)
      BMC Complement Altern Med. 2015 Jan 24;15:1. (PMID: 25617057)
      Bone Res. 2017 Jan 17;5:16044. (PMID: 28149655)
      Cardiovasc Res. 2006 Feb 15;69(3):562-73. (PMID: 16405877)
      Curr Opin Rheumatol. 2011 Sep;23(5):471-8. (PMID: 21788902)
      Arthritis Res Ther. 2012 Jan 30;14(1):201. (PMID: 22293240)
      Osteoarthritis Cartilage. 2016 Jul;24(7):1284-91. (PMID: 26915639)
      Inflammopharmacology. 2021 Oct;29(5):1475-1486. (PMID: 34468900)
      J Med Life. 2014 Mar 15;7(1):37-41. (PMID: 24653755)
      Life (Basel). 2022 Mar 16;12(3):. (PMID: 35330187)
      Front Physiol. 2019 Aug 20;10:1060. (PMID: 31481898)
      Food Chem Toxicol. 2021 Sep;155:112379. (PMID: 34197882)
      Mol Med Rep. 2017 Aug;16(2):1369-1375. (PMID: 28586061)
      Phytother Res. 2019 May;33(5):1457-1468. (PMID: 30838706)
      Evid Based Complement Alternat Med. 2020 May 21;2020:7381625. (PMID: 32565872)
      Planta Med. 2016 Apr;82(6):573-9. (PMID: 27054914)
      Rheumatology (Oxford). 2013 Aug;52(8):1408-17. (PMID: 23365148)
      Pharmaceuticals (Basel). 2021 Jul 10;14(7):. (PMID: 34358086)
      Fitoterapia. 2020 Oct;146:104694. (PMID: 32712132)
      BMC Complement Med Ther. 2022 Jan 27;22(1):25. (PMID: 35086536)
      Curr Drug Targets. 2007 Feb;8(2):305-13. (PMID: 17305508)
      Int J Immunopathol Pharmacol. 2016 Mar;29(1):140-6. (PMID: 26684635)
      Matrix Biol. 2016 Dec;56:57-73. (PMID: 27084377)
      Curr Drug Targets. 2010 May;11(5):599-613. (PMID: 20199390)
      Osteoarthritis Cartilage. 2010 Mar;18(3):279-88. (PMID: 19932675)
      Molecules. 2016 Oct 06;21(10):. (PMID: 27782055)
      Nat Rev Rheumatol. 2011 Jan;7(1):33-42. (PMID: 21119608)
      BMJ. 2011 Jan 11;342:c7086. (PMID: 21224324)
      Cell Signal. 2019 Jan;53:212-223. (PMID: 30312659)
    • Contributed Indexing:
      Keywords: Boswellia serrata; aggrecan; cytokines; matrix metalloproteinase; monosodium iodoacetate; osteoarthritis; type II collagen
    • الرقم المعرف:
      0 (Aggrecans)
      WF5188V710 (Iodoacetic Acid)
      0 (Tumor Necrosis Factor-alpha)
      0 (Interleukin-6)
      0 (RNA, Messenger)
    • الموضوع:
      Date Created: 20240328 Date Completed: 20240329 Latest Revision: 20240330
    • الموضوع:
      20240330
    • الرقم المعرف:
      PMC10970542
    • الرقم المعرف:
      10.3390/ijms25063218
    • الرقم المعرف:
      38542192